PCI Biotech Holding ASA (PCIB) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.501x

Based on the latest financial reports, PCI Biotech Holding ASA (PCIB) has a cash flow conversion efficiency ratio of -0.501x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-6.26 Million ≈ $-659.15K USD) by net assets (Nkr12.52 Million ≈ $1.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PCI Biotech Holding ASA (PCIB) balance sheet quality index to measure how much of total assets are equity-financed.

PCI Biotech Holding ASA - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how PCI Biotech Holding ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PCIB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

PCI Biotech Holding ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PCI Biotech Holding ASA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
SMG EUROPEAN RECOV. EO 1 F:RCVR	N/A
Global Gas Corporation NASDAQ:HGAS	0.137x
Sejahtera Bintang Abadi Textile Tbk JK:SBAT	-0.023x
M Winkworth PLC LSE:WINK	0.190x
Sino-German United AG F:SGU	N/A
Virpax Pharmaceuticals Inc NASDAQ:VRPX	3.142x
Europa Oil & Gas Holdings LSE:EOG	-0.080x
Baltic Bridge S.A. WAR:WIS	N/A

Annual Cash Flow Conversion Efficiency for PCI Biotech Holding ASA (2008–2024)

The table below shows the annual cash flow conversion efficiency of PCI Biotech Holding ASA from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see PCIB company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr23.45 Million ≈ $2.47 Million	Nkr-13.76 Million ≈ $-1.45 Million	-0.587x	-53.00%
2023-12-31	Nkr39.04 Million ≈ $4.11 Million	Nkr-14.97 Million ≈ $-1.58 Million	-0.383x	+62.72%
2022-12-31	Nkr57.40 Million ≈ $6.04 Million	Nkr-59.04 Million ≈ $-6.21 Million	-1.029x	-71.35%
2021-12-31	Nkr113.79 Million ≈ $11.97 Million	Nkr-68.31 Million ≈ $-7.19 Million	-0.600x	-46.79%
2020-12-31	Nkr189.24 Million ≈ $19.91 Million	Nkr-77.39 Million ≈ $-8.14 Million	-0.409x	-24.85%
2019-12-31	Nkr254.83 Million ≈ $26.82 Million	Nkr-83.47 Million ≈ $-8.78 Million	-0.328x	-258.30%
2018-12-31	Nkr339.95 Million ≈ $35.77 Million	Nkr-31.08 Million ≈ $-3.27 Million	-0.091x	+87.51%
2017-12-31	Nkr41.84 Million ≈ $4.40 Million	Nkr-30.62 Million ≈ $-3.22 Million	-0.732x	+73.17%
2016-12-31	Nkr13.09 Million ≈ $1.38 Million	Nkr-35.69 Million ≈ $-3.76 Million	-2.728x	-267.80%
2015-12-31	Nkr44.28 Million ≈ $4.66 Million	Nkr-32.84 Million ≈ $-3.46 Million	-0.742x	+78.66%
2014-12-31	Nkr9.11 Million ≈ $959.06K	Nkr-31.67 Million ≈ $-3.33 Million	-3.475x	-427.45%
2013-12-31	Nkr43.40 Million ≈ $4.57 Million	Nkr-28.59 Million ≈ $-3.01 Million	-0.659x	-88.59%
2012-12-31	Nkr69.71 Million ≈ $7.34 Million	Nkr-24.35 Million ≈ $-2.56 Million	-0.349x	-69.72%
2011-12-31	Nkr92.53 Million ≈ $9.74 Million	Nkr-19.05 Million ≈ $-2.00 Million	-0.206x	-104.92%
2010-12-31	Nkr105.42 Million ≈ $11.09 Million	Nkr-10.59 Million ≈ $-1.11 Million	-0.100x	+79.07%
2009-12-31	Nkr35.08 Million ≈ $3.69 Million	Nkr-16.84 Million ≈ $-1.77 Million	-0.480x	-151.50%
2008-12-31	Nkr49.30 Million ≈ $5.19 Million	Nkr-9.41 Million ≈ $-990.10K	-0.191x	--

About PCI Biotech Holding ASA

OL:PCIB Norway Biotechnology

Market Cap

$274.95K

Nkr2.61 Million NOK

Market Cap Rank

#31110 Global

#273 in Norway

Share Price

Nkr0.07

Change (1 day)

-39.13%

52-Week Range

Nkr0.07 - Nkr1.60

All Time High

Nkr86.30